Brain radiation boost may extend cancer control in lung and melanoma patients
NCT ID NCT05522660
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding a precise form of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases will be randomly assigned to receive either standard systemic treatment alone or standard treatment plus radiation. The goal is to see which approach delays brain tumor growth and maintains quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda ospedaliero-universitaria Senese Siena
RECRUITINGSiena, Italy
-
Christie NHS Manchester
RECRUITINGManchester, United Kingdom
-
Hospital La Fe
RECRUITINGValencia, Spain
-
Hospital Puerta de Hierro
RECRUITINGMajadahonda, Spain
-
Inselspital
RECRUITINGBern, Switzerland
-
Instituto Oncologico Veneto IRCCS
NOT_YET_RECRUITINGPadova, Italy
-
Istituto Nazionale Tumori "Regina Elena"
RECRUITINGRoma, Italy
-
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
RECRUITINGNaples, Italy
-
Kantonsspital Winterthur
RECRUITINGWinterthur, Switzerland
-
NKI-AVL
RECRUITINGAmsterdam, Netherlands
-
Policlinico Umberto 1
RECRUITINGRome, Italy
-
Royal Marsden (Sutton)
RECRUITINGLondon, United Kingdom
-
Santa Maria della Misericordia Hospital
RECRUITINGPerugia, Italy
-
Universitätsspital Zürich
RECRUITINGZurich, Switzerland
-
Vall Hebron Institute of Oncology (VHIO)
RECRUITINGBarcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can new drug cocktails reawaken the immune system against melanoma?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?